Skip To Main Content
Andrew Pitts on Muck Rack

Andrew Pitts

United Kingdom
As seen in: Lexology, RealClear Science, Mondaq, Interactive Investor International, Life Sciences Intellectual Property Review, mewburn.com, SoDo Mojo, HLS Forum on Corporate Governance, interactive investor (Podcast)
Money Observer editor from 1998 to 2015; now freelance. Far too tall.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Andrew

Contact Andrew, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Cravath Publishes Two Memos on SEC’s Proposed Filer Status and Registered Offering Reforms and Request for Comment on IPO Modernization

|
By John White, Philip J. Boeckman, Andrew Pitts
| cravath.com
On June 15, 2026, Cravath prepared two companion memos for its clients entitled “The Bold and the Creative (Part I): SEC Proposes to Rationalize Filer Status Framework and Extend Accommodations to Significantly More Registrants” and “The Bold and the Creative (Part II): SEC Proposes Significant Registered Offering Reforms Designed to Incentivize Companies to Go and Stay Public and Seeks Public Comment on Further Modernization.” Part I of the memo examines the SEC’s proposed rule amendments to...
Open in Who Shared Issue with article?

Orforglipron FDA Approval: Why the First Small-Molecule GLP-1 Pill Matters

|
By Andrew Pitts
| mewburn.com
The GLP-1 landscape changed on 1 April 2026, when the FDA approved Eli Lilly's orforglipron under the brand name Foundayo as the first non-peptide, small-molecule GLP-1 receptor agonist (GLP-1RA) anywhere in the world. The approval matters because it validates a long-sought oral small-molecule route to GLP-1 agonism, with potentially major consequences for convenience, manufacturing scale, pricing, and patent strategy. For two decades, GLP-1 drugs have been an exclusively peptide story.
Open in Who Shared Issue with article?

SEC Proposes Rule Amendments to Permit Optional Semiannual Reporting

|
By John White, Andrew Pitts, Elad L. Roisman
| cravath.com
On May 19, 2026, Cravath prepared a memo for its clients entitled “SEC Proposes Rule Amendments to Permit Optional Semiannual Reporting.” The memo examines the U.S. Securities and Exchange Commission’s recently proposed rule amendments that would allow SEC registrants required to file three quarterly reports per fiscal year under existing rules to elect to file a single semiannual report instead.
Open in Who Shared Issue with article?
See all 34 licensed articles (113 Total)